Switch theme
Sign up to access all valuation multiples
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.
2020
69
LTM Revenue n/a
LTM EBITDA n/a
-$1.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vigil Neuro has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Vigil Neuro achieved revenue of n/a and an EBITDA of -$89.2M.
Vigil Neuro expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vigil Neuro valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$88.5M | -$89.2M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$68.3M | -$82.6M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 28, 2025, Vigil Neuro's stock price is $2.
Vigil Neuro has current market cap of $83.5M, and EV of -$1.3M.
See Vigil Neuro trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$1.3M | $83.5M | XXX | XXX | XXX | XXX | $-2.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 28, 2025, Vigil Neuro has market cap of $83.5M and EV of -$1.3M.
Vigil Neuro's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Vigil Neuro's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Vigil Neuro and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$1.3M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.0x | XXX | XXX | XXX |
| P/E | -1.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpVigil Neuro's NTM/LTM revenue growth is Infinity%
Vigil Neuro's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.3M for the same period.
Over next 12 months, Vigil Neuro's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Vigil Neuro's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Vigil Neuro and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vigil Neuro acquired XXX companies to date.
Last acquisition by Vigil Neuro was XXXXXXXX, XXXXX XXXXX XXXXXX . Vigil Neuro acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Vigil Neuro founded? | Vigil Neuro was founded in 2020. |
| Where is Vigil Neuro headquartered? | Vigil Neuro is headquartered in United States of America. |
| How many employees does Vigil Neuro have? | As of today, Vigil Neuro has 69 employees. |
| Who is the CEO of Vigil Neuro? | Vigil Neuro's CEO is Dr. Ivana Magovcevic-Liebisch, J.D.,PhD. |
| Is Vigil Neuro publicy listed? | Yes, Vigil Neuro is a public company listed on NAS. |
| What is the stock symbol of Vigil Neuro? | Vigil Neuro trades under VIGL ticker. |
| When did Vigil Neuro go public? | Vigil Neuro went public in 2022. |
| Who are competitors of Vigil Neuro? | Similar companies to Vigil Neuro include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Vigil Neuro? | Vigil Neuro's current market cap is $83.5M |
| Is Vigil Neuro profitable? | Yes, Vigil Neuro is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
